Using Models to Predict the Future: What to Do When the Data Run Out?

Although clinical trials often provide “best evidence” comparing the effectiveness of alternative management strategies, such evidence can be limited in duration or in the results reported, causing clinicians and policy analysts to wonder “what if?” Models of the clinical prognosis—often spanning pa...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2012-05, Vol.91 (5), p.769-771
Main Authors: Pauker, S G, Goss, F R
Format: Article
Language:English
Subjects:
Angioplasty, Balloon, Coronary
Aryl Hydrocarbon Hydroxylases - genetics
Cytochrome P-450 CYP2C19
Female
Humans
Male
Piperazines - therapeutic use
Platelet Aggregation Inhibitors - therapeutic use
Prasugrel Hydrochloride
Thiophenes - therapeutic use
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although clinical trials often provide “best evidence” comparing the effectiveness of alternative management strategies, such evidence can be limited in duration or in the results reported, causing clinicians and policy analysts to wonder “what if?” Models of the clinical prognosis—often spanning patients’ lifetimes (the “long haul”)—are perhaps weaker evidence, but can help answer questions about the management of individual patients and place that best evidence into the context of clinical reality. Clinical Pharmacology & Therapeutics (2012); 91 5, 769–771. doi:10.1038/clpt.2012.25
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2012.25